Loading
Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes.
No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.
Baltimore · cancer center | United States | 0 | 3,313 | 48,889 | #10 | ||
Boston · cancer center Programme: Breast oncology (KEYNOTE-522, ADCs) | United States | 1 | 4,356 | 73,185 | none recorded | #15 | |
Lausanne · hospital | Switzerland | none recorded | 0 | 814 | 27,985 | - | |
Brussels · cancer center Programme: Breast International Group, Breast cancer genomics and ctDNA | Belgium | none recorded | 0 | 469 | 8,888 | - | |
Philadelphia, PA · cancer center | United States | 0 | 247 | 1,453 | - | ||
Chicago, IL · cancer center | United States | 0 | 141 | 4,103 | - | ||
Salt Lake City, UT · cancer center | United States | 0 | not matched | - | - | ||
Santa Monica, CA · consortium | United States | none recorded | 0 | not matched | - | none recorded | - |
These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with Luminal androgen receptor triple-negative breast cancer but is thinly recorded here will look small.
Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.